What is better for psychiatry: Titrated or fixed concentrations of nitrous oxide?

Medication dosages are crucial-no single dose fits all. My paper compares the safety, scientific and practical applicability of fixed 25-50% concentrations of nitrous oxide (NO) with the variable titrated concentrations of Psychotropic Analgesic NO (PAN), as used in dentistry, and neuropsychiatry. A crucial difference is that PAN is always titrated, an open circuit (nasal mask), to the concentration (dose), which ensures full consciousness, cooperation, comfort and relaxation.

Mini-Review: A Brief History of Nitrous Oxide (N2O) Use in Neuropsychiatry.

Background: Joseph Priestley's discovery of nitrous oxide (N2O) was recorded in 1772. In the late 1790's, Humphry Davy experimented with the psychotropic properties of N2O, describing his observations in a book, published in 1800. A dentist, Horace Wells discovered anaesthesia with N2O in 1844.

Cause of Cambrian Explosion - Terrestrial or Cosmic?

We review the salient evidence consistent with or predicted by the Hoyle-Wickramasinghe (H-W) thesis of Cometary (Cosmic) Biology. Much of this physical and biological evidence is multifactorial. One particular focus are the recent studies which date the emergence of the complex retroviruses of vertebrate lines at or just before the Cambrian Explosion of ∼500 Ma.

Combined cannabis/methaqualone withdrawal treated with psychotropic analgesic nitrous oxide.

This article reports the first single-blind study using psychotropic analgesic nitrous oxide (PAN) for treating acute withdrawal states following the abuse of methaqualone combined and smoked with cannabis. Smoked methaqualone combined with cannabis is called "white pipe" (WP). South Africa is the only country in the world where WP is a major form of substance abuse.

Psychotropic analgesic nitrous oxide for acute cocaine withdrawal in man.

This article reports the first single-blind study using psychotropic analgesic nitrous oxide (PAN) for treating acute withdrawal states following cocaine abuse. Thirty-one of the 33 cases responded by a reduction of symptom scores of 50% or more, which clinical experience has shown to be synonymous with observed recovery. Five subjects were placebo responders without further improvement following PAN.

Enlarged double-blind randomised trial of benzodiazepines against psychotropic analgesic nitrous oxide for alcohol withdrawal.

We report a randomised double-blind controlled study with an enlarged cohort of participants (N = 51) using psychotropic analgesic nitrous oxide (PAN) versus benzodiazepines (BZs) for treating acute alcoholic withdrawal states. An additional 28 participants having received a BZ the night previous to the study were pooled with the previously analysed 23 (with no additional BZ). These pooled results showed that PAN is superior to a BZ regimen at P = .

Randomized double-blind trial of psychotropic analgesic nitrous oxide compared with diazepam for alcohol withdrawal state.

In this article, we report the first randomized double-blind controlled study of the use of psychotropic analgesic nitrous oxide (PAN) vs. a single dose of benzodiazepine (diazepam) for treating acute alcoholic withdrawal states. In previous studies, it was demonstrated that a single treatment of PAN was sufficient to reverse 90% of acute alcoholic withdrawal states within the first 60 minutes of administration with lasting effect in a single-blind manner.

Antidepressants are not drugs of abuse or dependence.

There is a view among both the lay and medical audience that antidepressants are addictive. Non-compliance may arise as a result, with fatal consequences in some cases. In spite of the fact that anti-depressants have not proved to be drugs of abuse or dependence, confusion exists in the literature, particularly regarding the definition of the terms misuse and abuse in opioid addicts.

Clinical role and mechanisms of action of analgesic nitrous oxide.

We give a brief history and development of the use of analgesic nitrous oxide in various clinical situations, emphasizing the very important difference between analgesic and anesthetic concentrations of the gas. We give evidence for the opioid nature of analgesic nitrous oxide and the probable role that these opioid properties play in its clinical effects. Its uniqueness among the opioids arises from its ability to safely stimulate both mu and kappa opioid receptors thereby modulating these systems, which are at times antagonistic to each other.

Role of dopamine mesolimbic system in opioid action of psychotropic analgesic nitrous oxide in alcohol and drug withdrawal.

Psychotropic analgesic nitrous oxide (PAN) has been used successfully in the treatment of alcohol and drug withdrawal in > 15,000 cases. It is an opioid and thus the first gaseous member of the opioid family. We propose the existence of two mutually antagonistic opioid systems as underlying addictive withdrawal states; mu and kappa.

Pharmacology of psychotropic analgesic nitrous oxide as a multipotent opioid agonist.

We show that psychotropic analgesic nitrous oxide is a partial opioid agonist since it fulfills all the following criteria to be classified as an opioid: 1) its effects are antagonised by various opioid antagonists including stereospecific naloxone antagonism; 2) it is cross tolerant with morphine; 3) its effects are potentiated by enkephalinase inhibition; 4) it provokes the release of endogenous opioids; 5) it interferes at low concentrations with specific opioid ligand binding at radio-receptor assay. Like the prototype opioid morphine it acts directly and indirectly at opioid receptors. PAN, although considered an exogenous inorganic molecule was also the first gas to be shown to have a direct role in influencing neurotransmission.

Psychotropic analgesic nitrous oxide for treating alcohol withdrawal in an outpatient setting.

In a retrospective study of 500 patients we present evidence that psychotropic analgesic nitrous oxide (PAN) can be used safely and successfully as an out-patient treatment for the AWS in the vast majority of cases. A feature of the PAN therapy is the rapidity of recovery of patients within 60 minutes; which is in stark contrast to that found when traditional benzodiazepine medication regimens are used. Our work confirms earlier findings confined to in-patients.

Psychotropic analgesic nitrous oxide and neurotransmitter mechanisms involved in the alcohol withdrawal state.

We relate the extremely rapid and lasting beneficial effects of psychotropic analgesic nitrous oxide (PAN) on the alcohol withdrawal state (AWS) to the underlying neurotransmitter system disturbances and clinical findings. PAN is an opioid and its main therapeutic effects are produced by stimulating the underactive endogenous opioid system (EOS) found in the AWS. In common with other opioids, PAN also acts on other neurotransmitter systems.